298 related articles for article (PubMed ID: 27271923)
1. Diffusion-weighted magnetic resonance imaging predicts survival in patients with liver-predominant metastatic colorectal cancer shortly after selective internal radiation therapy.
Schmeel FC; Simon B; Sabet A; Luetkens JA; Träber F; Schmeel LC; Ezziddin S; Schild HH; Hadizadeh DR
Eur Radiol; 2017 Mar; 27(3):966-975. PubMed ID: 27271923
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of pretreatment diffusion-weighted magnetic resonance imaging for outcome prediction of colorectal cancer liver metastases undergoing 90Y-microsphere radioembolization.
Schmeel FC; Simon B; Luetkens JA; Träber F; Meyer C; Schmeel LC; Sabet A; Ezziddin S; Schild HH; Hadizadeh DR
J Cancer Res Clin Oncol; 2017 Aug; 143(8):1531-1541. PubMed ID: 28317063
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of ADC measurements in predicting overall survival in patients undergoing
Alis D; Durmaz ESM; Gulsen F; Bas A; Kabasakal L; Sager S; Numan F
Clin Imaging; 2019; 57():124-130. PubMed ID: 31220677
[TBL] [Abstract][Full Text] [Related]
4. Fat-free muscle area measured by magnetic resonance imaging predicts overall survival of patients undergoing radioembolization of colorectal cancer liver metastases.
Faron A; Pieper CC; Schmeel FC; Sprinkart AM; Kuetting DLR; Fimmers R; Trebicka J; Schild HH; Meyer C; Thomas D; Luetkens JA
Eur Radiol; 2019 Sep; 29(9):4709-4717. PubMed ID: 30689036
[TBL] [Abstract][Full Text] [Related]
5. Early post-treatment FDG PET predicts survival after 90Y microsphere radioembolization in liver-dominant metastatic colorectal cancer.
Sabet A; Meyer C; Aouf A; Sabet A; Ghamari S; Pieper CC; Mayer K; Biersack HJ; Ezziddin S
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):370-6. PubMed ID: 25351506
[TBL] [Abstract][Full Text] [Related]
6. Diffusion-weighted MRI Is Superior to PET/CT in Predicting Survival of Patients Undergoing
Barabasch A; Heinzel A; Bruners P; Kraemer NA; Kuhl CK
Radiology; 2018 Sep; 288(3):764-773. PubMed ID: 29786487
[TBL] [Abstract][Full Text] [Related]
7. Diagnostic accuracy of diffusion-weighted magnetic resonance imaging versus positron emission tomography/computed tomography for early response assessment of liver metastases to Y90-radioembolization.
Barabasch A; Kraemer NA; Ciritsis A; Hansen NL; Lierfeld M; Heinzel A; Trautwein C; Neumann U; Kuhl CK
Invest Radiol; 2015 Jun; 50(6):409-15. PubMed ID: 25763526
[TBL] [Abstract][Full Text] [Related]
8. Early detection of therapeutic response to hepatic arterial infusion chemotherapy of liver metastases from colorectal cancer using diffusion-weighted MR imaging.
Marugami N; Tanaka T; Kitano S; Hirohashi S; Nishiofuku H; Takahashi A; Sakaguchi H; Matsuoka M; Otsuji T; Takahama J; Higashiura W; Kichikawa K
Cardiovasc Intervent Radiol; 2009 Jul; 32(4):638-46. PubMed ID: 19238482
[TBL] [Abstract][Full Text] [Related]
9. Early prediction of anticancer effects with diffusion-weighted MR imaging in patients with colorectal liver metastases following selective internal radiotherapy.
Dudeck O; Zeile M; Wybranski C; Schulmeister A; Fischbach F; Pech M; Wieners G; Rühl R; Grosser O; Amthauer H; Ricke J
Eur Radiol; 2010 Nov; 20(11):2699-706. PubMed ID: 20563725
[TBL] [Abstract][Full Text] [Related]
10. Selective Internal Yttrium-90 Radioembolization Therapy (90Y-SIRT) Versus Best Supportive Care in Patients With Unresectable Metastatic Melanoma to the Liver Refractory to Systemic Therapy: Safety and Efficacy Cohort Study.
Xing M; Prajapati HJ; Dhanasekaran R; Lawson DH; Kokabi N; Eaton BR; Kim HS
Am J Clin Oncol; 2017 Feb; 40(1):27-34. PubMed ID: 25089529
[TBL] [Abstract][Full Text] [Related]
11. Tumor response after yttrium-90 radioembolization for hepatocellular carcinoma: comparison of diffusion-weighted functional MR imaging with anatomic MR imaging.
Rhee TK; Naik NK; Deng J; Atassi B; Mulcahy MF; Kulik LM; Ryu RK; Miller FH; Larson AC; Salem R; Omary RA
J Vasc Interv Radiol; 2008 Aug; 19(8):1180-6. PubMed ID: 18656011
[TBL] [Abstract][Full Text] [Related]
12. Value of diffusion weighted MR imaging as an early surrogate parameter for evaluation of tumor response to high-dose-rate brachytherapy of colorectal liver metastases.
Wybranski C; Zeile M; Löwenthal D; Fischbach F; Pech M; Röhl FW; Gademann G; Ricke J; Dudeck O
Radiat Oncol; 2011 Apr; 6(1):43. PubMed ID: 21524305
[TBL] [Abstract][Full Text] [Related]
13. Metabolic tumor volume and total lesion glycolysis on FDG-PET/CT can predict overall survival after (90)Y radioembolization of colorectal liver metastases: A comparison with SUVmax, SUVpeak, and RECIST 1.0.
Shady W; Kishore S; Gavane S; Do RK; Osborne JR; Ulaner GA; Gonen M; Ziv E; Boas FE; Sofocleous CT
Eur J Radiol; 2016 Jun; 85(6):1224-31. PubMed ID: 27161074
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of selective internal radiation therapy for chemorefractory colorectal cancer liver metastases progressing after hepatic arterial pump and systemic chemotherapy.
Sofocleous CT; Garcia AR; Pandit-Taskar N; Do KG; Brody LA; Petre EN; Capanu M; Longing AP; Chou JF; Carrasquillo JA; Kemeny NE
Clin Colorectal Cancer; 2014 Mar; 13(1):27-36. PubMed ID: 24370352
[TBL] [Abstract][Full Text] [Related]
15. Correlation of radiation dose and activity with clinical outcomes in metastatic colorectal cancer after selective internal radiation therapy using yttrium-90 resin microspheres.
Badiyan S; Bhooshan N; Chuong MD; Sharma N; Akhter N; Etezadi V; Hausner P; Kudryasheva S; Kaiser A; Becker S; Guerrero M; Yi BY
Nucl Med Commun; 2018 Oct; 39(10):915-920. PubMed ID: 30124600
[TBL] [Abstract][Full Text] [Related]
16. Yttrium-90 Hepatic Radioembolization for Advanced Chemorefractory Metastatic Colorectal Cancer: Survival Outcomes Based on Right- Versus Left-Sided Primary Tumor Location.
Wu V; Li MD; Goodwin JS; Wehrenberg-Klee EP; Zurkiya O; Kalva SP; Ganguli S
AJR Am J Roentgenol; 2021 Nov; 217(5):1141-1152. PubMed ID: 33594907
[No Abstract] [Full Text] [Related]
17. Single-institution experience with selective internal radiation therapy (SIRT) for the treatment of unresectable colorectal liver metastases.
O'Leary C; Greally M; McCaffrey J; Hughes P; Lawler LLP; O'Connell M; Geoghegan T; Farrelly C
Ir J Med Sci; 2019 Feb; 188(1):43-53. PubMed ID: 29511912
[TBL] [Abstract][Full Text] [Related]
18. 18F-FDG PET/CT predicts survival after radioembolization of hepatic metastases from breast cancer.
Haug AR; Tiega Donfack BP; Trumm C; Zech CJ; Michl M; Laubender RP; Uebleis C; Bartenstein P; Heinemann V; Hacker M
J Nucl Med; 2012 Mar; 53(3):371-7. PubMed ID: 22331219
[TBL] [Abstract][Full Text] [Related]
19. Validation of several SUV-based parameters derived from 18F-FDG PET for prediction of survival after SIRT of hepatic metastases from colorectal cancer.
Fendler WP; Philippe Tiega DB; Ilhan H; Paprottka PM; Heinemann V; Jakobs TF; Bartenstein P; Hacker M; Haug AR
J Nucl Med; 2013 Aug; 54(8):1202-8. PubMed ID: 23729697
[TBL] [Abstract][Full Text] [Related]
20. The role of pre-treatment diffusion-weighted MRI in predicting long-term outcome of colorectal liver metastasis.
Tam HH; Collins DJ; Brown G; Chau I; Cunningham D; Leach MO; Koh DM
Br J Radiol; 2013 Oct; 86(1030):20130281. PubMed ID: 23995873
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
